A case of bone marrow–liver–spleen type diffuse large B-cell lymphoma: importance of rapid diagnosis and therapeutic intervention
- 1Department of Hematology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan, Department of Pathology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan
Abstract
Bone marrow–liver–spleen (BLS)-type diffuse large B-cell lymphoma (DLBCL) is a rare and aggressive variant characterized by primary involvement of the bone marrow, liver, and spleen without lymphadenopathy. We describe the case of a 73-year-old woman who presented with multiorgan failure complicated by disseminated intravascular coagulation and clinical features suggestive of secondary hemophagocytic lymphohistiocytosis. Prompt initiation of intensive chemotherapy (R-CHOP: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone) guided by characteristic clinical findings including bone marrow smear examination, resulted in rapid clinical improvement and prolonged survival.
Rather than representing an unusual diagnostic dilemma, this case illustrates a clinically characteristic and educational presentation of BLS-type DLBCL and highlights the importance of timely lymphoma-directed treatment based on readily available hematologic evidence.
Related
- Viral states and immune competence in Epstein–Barr virus-positive diffuse large B-cell lymphoma: conditions for therapeutic targeting
- Resistance to covalent Bruton's tyrosine kinase inhibitors in diffuse large B-cell lymphoma: Molecular mechanisms and therapeutic implications (Review)
- MUTATIONAL PROFILE OF DIFFUSE LARGE B-CELL LYMPHOMA DETECTED IN CIRCULATING TUMOR DNA AT DIAGNOSIS
- Intelligent Hydrogel Sensors for Health Monitoring and Therapeutic Intervention: From Material Design to Integrated Diagnosis and Treatment.
- Nasopharyngeal diffuse large b-cell lymphoma in a teenage presenting with cavernous sinus syndrome: A case report
BibTeX
@article{eda2026case,
title = {{A case of bone marrow–liver–spleen type diffuse large B-cell lymphoma: importance of rapid diagnosis and therapeutic intervention}},
author = {Hitomi Eda and Kaoru Furihata and Fumiya Ogasawara},
journal = {Journal of Clinical and Experimental Hematopathology : JCEH},
year = {2026},
month = jul,
doi = {10.3960/jslrt.26011},
url = {https://doi.org/10.3960/jslrt.26011},
note = {CC BY-NC-SA 4.0},
}
RIS
TY - JOUR
TI - A case of bone marrow–liver–spleen type diffuse large B-cell lymphoma: importance of rapid diagnosis and therapeutic intervention
AU - Hitomi Eda
AU - Kaoru Furihata
AU - Fumiya Ogasawara
PY - 2026
DA - 2026/07/30
JO - Journal of Clinical and Experimental Hematopathology : JCEH
DO - 10.3960/jslrt.26011
UR - https://doi.org/10.3960/jslrt.26011
AB - Bone marrow–liver–spleen (BLS)-type diffuse large B-cell lymphoma (DLBCL) is a rare and aggressive variant characterized by primary involvement of the bone marrow, liver, and spleen without lymphadenopathy. We describe the case of a 73-year-old woman who presented with multiorgan failure complicated by disseminated intravascular coagulation and clinical features suggestive of secondary hemophagocytic lymphohistiocytosis. Prompt initiation of intensive chemotherapy (R-CHOP: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone) guided by characteristic clinical findings including bone marrow smear examination, resulted in rapid clinical improvement and prolonged survival. Rather than representing an unusual diagnostic dilemma, this case illustrates a clinically characteristic and educational presentation of BLS-type DLBCL and highlights the importance of timely lymphoma-directed treatment based on readily available hematologic evidence.
SN - 1346-4280
SN - 1880-9952
ER -